## **Darius Moradpour**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8127772/publications.pdf

Version: 2024-02-01

34105 21540 114 13,344 128 52 citations h-index g-index papers 131 131 131 11467 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Hepatitis E virus RNAâ€dependent RNA polymerase is involved in RNA replication and infectious particle production. Hepatology, 2022, 75, 170-181.	<b>7.</b> 3	8
2	High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. Clinical Microbiology and Infection, 2022, 28, 611.e1-611.e7.	6.0	3
3	Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis., 2022, 152, w30138.		O
4	The histologic presentation of hepatitis E reflects patients' immune status and pre-existing liver condition. Modern Pathology, 2021, 34, 233-248.	5.5	16
5	Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center. PLoS ONE, 2021, 16, e0250347.	2.5	9
6	Case Report: SARS-CoV-2 as an unexpected causal agent of isolated febrile hepatitis. F1000Research, 2021, 10, 400.	1.6	1
7	Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. Swiss Medical Weekly, 2021, 151, w20502.	1.6	2
8	Hepatitis A and E – Differences and commonalities. Journal of Hepatology, 2020, 72, 578-580.	3.7	6
9	Hepatitis E virus finds its path through the gut. Gut, 2020, 69, 796-798.	12.1	5
10	All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). Open Forum Infectious Diseases, 2020, 7, ofaa308.	0.9	6
11	Acute immune thrombocytopaenic purpura in a patient with COVID-19 and decompensated cirrhosis. BMJ Case Reports, 2020, 13, e236815.	0.5	19
12	OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. PLoS ONE, 2020, 15, e0236447.	2.5	7
13	Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis. JHEP Reports, 2020, 2, 100120.	4.9	15
14	Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis. Journal of Hepatology, 2020, 73, 967-970.	3.7	10
15	On the Host Side of the Hepatitis E Virus Life Cycle. Cells, 2020, 9, 1294.	4.1	14
16	Neurologic complications of acute hepatitis E virus infection. Neurology: Neuroimmunology and NeuroInflammation, 2020, $7$ , .	6.0	32
17	Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis. Hepatology, 2020, 71, 2135-2148.	7.3	46
18	Combined Lung and Liver Transplantation for Short Telomere Syndrome. Liver Transplantation, 2020, 26, 840-844.	2.4	10

#	Article	IF	Citations
19	Recombinant Hepatitis E Viruses Harboring Tags in the ORF1 Protein. Journal of Virology, 2019, 93, .	3.4	39
20	Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report. BMC Gastroenterology, 2019, 19, 76.	2.0	21
21	Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. Journal of Autoimmunity, 2019, 102, 89-95.	6.5	16
22	Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland. Journal of Hepatology, 2019, 70, 1023-1025.	3.7	47
23	Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients. Journal of Viral Hepatitis, 2019, 26, 271-277.	2.0	4
24	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Research, 2018, 248, 53-62.	2.2	124
25	Rapid Remission of Graves' Hyperthyroidism Without Thionamides Under Immunosuppressive Treatment for Concomitant Autoimmune Hepatitis. Thyroid, 2018, 28, 276-278.	4.5	3
26	Pan-Genotype Hepatitis E Virus Replication in Stem Cell–Derived Hepatocellular Systems. Gastroenterology, 2018, 154, 663-674.e7.	1.3	46
27	EASL Clinical Practice Guidelines on hepatitis E virus infection. Journal of Hepatology, 2018, 68, 1256-1271.	3.7	425
28	Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. Liver International, 2018, 38, 619-626.	3.9	25
29	Late hepatitis B reactivation following directâ€acting antiviral–based treatment of recurrent hepatitis C in an antiâ€HBc–positive liver transplant recipient. Hepatology, 2018, 67, 791-793.	7.3	12
30	Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication. Cellular Microbiology, 2018, 20, e12804.	2.1	28
31	Palmitoylation mediates membrane association of hepatitis E virus ORF3 protein and is required for infectious particle secretion. PLoS Pathogens, 2018, 14, e1007471.	4.7	60
32	Glycogen Synthase Kinase $3\hat{l}^2$ Enhances Hepatitis C Virus Replication by Supporting miR-122. Frontiers in Microbiology, 2018, 9, 2949.	3.5	13
33	Targeting Endoplasmic Reticulum and/or Mitochondrial Ca2+ Fluxes as Therapeutic Strategy for HCV Infection. Frontiers in Chemistry, 2018, 6, 73.	3.6	15
34	Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs. Journal of Steroid Biochemistry and Molecular Biology, 2018, 183, 142-151.	2.5	12
35	Hepatic manifestations of Wilson's disease: 12-year experience in a Swiss tertiary referral centre. Swiss Medical Weekly, 2018, 148, w14699.	1.6	6
36	A systematic review and metaâ€analysis of <scp>HCV</scp> clearance. Liver International, 2017, 37, 1431-1445.	3.9	37

#	Article	IF	CITATIONS
37	Visualization of hepatitis E virus RNA and proteins in the human liver. Journal of Hepatology, 2017, 67, 471-479.	3.7	49
38	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases, 2017, 64, 1275-1278.	5.8	23
39	Clinical phenotype and outcome of hepatitis E virus–associated neuralgic amyotrophy. Neurology, 2017, 89, 909-917.	1.1	75
40	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. Journal of Hepatology, 2017, 66, 297-303.	3.7	101
41	<i>BRIP1</i> coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. Oncotarget, 2017, 8, 62842-62857.	1.8	7
42	Hepatitis E virus infection as a direct cause of neuralgic amyotrophy. Muscle and Nerve, 2016, 54, 325-327.	2.2	24
43	Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing. Gut, 2016, 65, 1583-1584.	12.1	5
44	Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania. International Journal of Infectious Diseases, 2016, 46, 8-10.	3.3	17
45	Cell-free expression, purification, and membrane reconstitution for NMR studies of the nonstructural protein 4B from hepatitis C virus. Journal of Biomolecular NMR, 2016, 65, 87-98.	2.8	25
46	Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infectious Diseases, The, 2016, 16, 606-617.	9.1	118
47	Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease. Journal of Hepatology, 2016, 65, 1063-1065.	3.7	7
48	Future landscape of hepatitis C research – Basic, translational and clinical perspectives. Journal of Hepatology, 2016, 65, S143-S155.	3.7	26
49	Reply. Gastroenterology, 2016, 150, 1690-1691.	1.3	0
50	A mouse model for hepatitis E virus infection. Journal of Hepatology, 2016, 64, 1003-1005.	3.7	2
51	Update on hepatitis E virology: Implications for clinical practice. Journal of Hepatology, 2016, 65, 200-212.	3.7	165
52	Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. Gastroenterology, 2016, 150, 82-85.e4.	1.3	175
53	Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. PLoS ONE, 2016, 11, e0155464.	2.5	9
54	Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report. BMC Gastroenterology, 2015, 15, 38.	2.0	2

#	Article	IF	CITATIONS
55	Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN- $\hat{l}^2$ induction by efficient MAVS cleavage. Journal of Hepatology, 2015, 62, 779-784.	3.7	12
56	Wheat germ cell-free expression: Two detergents with a low critical micelle concentration allow for production of soluble HCV membrane proteins. Protein Expression and Purification, 2015, 105, 39-46.	1.3	24
57	Clinical Significance of the CCR5delta32 Allele in Hepatitis C. PLoS ONE, 2014, 9, e106424.	2.5	7
58	Determinants for Membrane Association of the Hepatitis C Virus NS2 Protease Domain. Journal of Virology, 2014, 88, 6519-6523.	3.4	19
59	Aminoterminal Amphipathic α-Helix AH1 of Hepatitis C Virus Nonstructural Protein 4B Possesses a Dual Role in RNA Replication and Virus Production. PLoS Pathogens, 2014, 10, e1004501.	4.7	46
60	Reduced IFN $\hat{l}$ »4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nature Communications, 2014, 5, 5699.	12.8	117
61	Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease. Hepatology, 2014, 59, 423-433.	7.3	41
62	NS2 Proteins of GB Virus B and Hepatitis C Virus Share Common Protease Activities and Membrane Topologies. Journal of Virology, 2014, 88, 7426-7444.	3.4	10
63	Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression. Biochemical Pharmacology, 2014, 89, 545-556.	4.4	15
64	GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. Cancer & Metabolism, 2014, 2, 11.	5.0	115
65	Vitamin D Receptor and Jak–STAT Signaling Crosstalk Results in Calcitriol-Mediated Increase of Hepatocellular Response to IFN-α. Journal of Immunology, 2014, 192, 6037-6044.	0.8	81
66	Hepatitis C Virus Proteins: From Structure to Function. Current Topics in Microbiology and Immunology, 2013, 369, 113-142.	1.1	227
67	Targeting mitochondria in the infection strategy of the hepatitis C virus. International Journal of Biochemistry and Cell Biology, 2013, 45, 156-166.	2.8	23
68	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. Antimicrobial Agents and Chemotherapy, 2013, 57, 3147-3158.	3.2	22
69	Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. PLoS ONE, 2013, 8, e64053.	2.5	59
70	Analysis of hepatitis C virus resistance to silibinin <i>in vitro</i> and <i>in vivo</i> points to a novel mechanism involving nonstructural protein 4B. Hepatology, 2013, 57, 953-963.	7.3	44
71	An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population. PLoS ONE, 2013, 8, e62980.	2.5	51
72	A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. PLoS ONE, 2012, 7, e40159.	2.5	60

#	Article	IF	CITATIONS
73	Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology, 2012, 55, 1038-1047.	7.3	36
74	Replication of Hepatitis C Virus. , 2012, , 97-110.		1
75	Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Journal of Hepatology, 2011, 55, 322-327.	3.7	115
76	Viral genotype-specific role of PNPLA3 , PPARG , MTTP, and IL28B in hepatitis C virus-associated steatosis. Journal of Hepatology, 2011, 55, 529-535.	3.7	98
77	Hepatitis E Virus Seroprevalence among Blood Donors in Southwest Switzerland. PLoS ONE, 2011, 6, e21150.	2.5	88
78	NS4B Self-Interaction through Conserved C-Terminal Elements Is Required for the Establishment of Functional Hepatitis C Virus Replication Complexes. Journal of Virology, 2011, 85, 6963-6976.	3.4	107
79	NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly. PLoS Pathogens, 2011, 7, e1001278.	4.7	142
80	Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology, 2010, 51, 1127-1136.	7.3	115
81	Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Reviews in Medical Virology, 2010, 20, 117-129.	8.3	101
82	Amphipathic α-Helix AH2 Is a Major Determinant for the Oligomerization of Hepatitis C Virus Nonstructural Protein 4B. Journal of Virology, 2010, 84, 12529-12537.	3.4	73
83	Structural and Functional Studies of Nonstructural Protein 2 of the Hepatitis C Virus Reveal Its Key Role as Organizer of Virion Assembly. PLoS Pathogens, 2010, 6, e1001233.	4.7	162
84	Hepatitis C Virus-Linked Mitochondrial Dysfunction Promotes Hypoxia-Inducible Factor 1α-Mediated Glycolytic Adaptation. Journal of Virology, 2010, 84, 647-660.	3.4	145
85	An Amphipathic α-Helix at the C Terminus of Hepatitis C Virus Nonstructural Protein 4B Mediates Membrane Association. Journal of Virology, 2009, 83, 11378-11384.	3.4	60
86	Identification of a Novel Determinant for Membrane Association in Hepatitis C Virus Nonstructural Protein 4B. Journal of Virology, 2009, 83, 6257-6268.	3.4	91
87	Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference. Hepatology, 2009, 50, 46-55.	7.3	138
88	Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology, 2009, 51, 655-666.	3.7	247
89	New insights into hepatitis B and C virus co-infection. Journal of Hepatology, 2009, 51, 423-425.	3.7	17
90	Investigation of the Hepatitis C Virus Replication Complex. Methods in Molecular Biology, 2009, 510, 195-209.	0.9	4

#	Article	IF	CITATIONS
91	Suppression of short interfering RNA-mediated gene silencing by the structural proteins of hepatitis C virus. Journal of General Virology, 2008, 89, 2761-2766.	2.9	34
92	Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14545-14550.	7.1	119
93	A Dynamic View of Hepatitis C Virus Replication Complexes. Journal of Virology, 2008, 82, 10519-10531.	3.4	119
94	Chronic hepatitis C: Portrait of a silent epidemic and the etiologic agent., 2008,, 95-120.		0
95	euHCVdb: the European hepatitis C virus database. Nucleic Acids Research, 2007, 35, D363-D366.	14.5	128
96	Replication of hepatitis C virus. Nature Reviews Microbiology, 2007, 5, 453-463.	28.6	1,158
97	Pathogenesis of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2005, 17, 477-483.	1.6	142
98	Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature, 2005, 437, 1167-1172.	27.8	2,136
99	Function follows form: The structure of the N-terminal domain of HCV NS5A. Hepatology, 2005, 42, 732-735.	<b>7.</b> 3	37
100	Hepatitis C virus comes full circle: Production of recombinant infectious virus in tissue culture. Hepatology, 2005, 42, 1264-1269.	7.3	7
101	Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins. Journal of General Virology, 2005, 86, 1737-1746.	2.9	6
102	Structure and Function of the Membrane Anchor Domain of Hepatitis C Virus Nonstructural Protein 5A. Journal of Biological Chemistry, 2004, 279, 40835-40843.	3.4	249
103	Membrane Association of the RNA-Dependent RNA Polymerase Is Essential for Hepatitis C Virus RNA Replication. Journal of Virology, 2004, 78, 13278-13284.	3.4	121
104	A primer on the molecular virology of hepatitis C. Liver International, 2004, 24, 519-525.	3.9	21
105	Structural biology of hepatitis C virus. Hepatology, 2004, 39, 5-19.	7.3	558
106	Insertion of Green Fluorescent Protein into Nonstructural Protein 5A Allows Direct Visualization of Functional Hepatitis C Virus Replication Complexes. Journal of Virology, 2004, 78, 7400-7409.	3.4	226
107	Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Research, 2003, 60, 103-109.	4.1	136
108	Identification of the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic Replicons. Journal of Virology, 2003, 77, 5487-5492.	3.4	558

7

#	Article	IF	CITATIONS
109	The Hepatitis C Virus RNA-Dependent RNA Polymerase Membrane Insertion Sequence Is a Transmembrane Segment. Journal of Virology, 2002, 76, 13088-13093.	3.4	81
110	Expression of Hepatitis C Virus Proteins Induces Distinct Membrane Alterations Including a Candidate Viral Replication Complex. Journal of Virology, 2002, 76, 5974-5984.	3.4	721
111	Functional Properties of a Monoclonal Antibody Inhibiting the Hepatitis C Virus RNA-dependent RNA Polymerase. Journal of Biological Chemistry, 2002, 277, 593-601.	3.4	46
112	Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends in Cell Biology, 2002, 12, 517-523.	7.9	111
113	Hepatitis C: molecular virology and antiviral targets. Trends in Molecular Medicine, 2002, 8, 476-482.	6.7	51
114	The Hepatitis C Virus Nonstructural Protein 4B Is an Integral Endoplasmic Reticulum Membrane Protein. Virology, 2001, 284, 70-81.	2.4	187
115	Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology, 2001, 33, 1282-1287.	7.3	30
116	Determinants for Membrane Association of the Hepatitis C Virus RNA-dependent RNA Polymerase. Journal of Biological Chemistry, 2001, 276, 44052-44063.	3.4	172
117	Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. Journal of General Virology, 2001, 82, 723-733.	2.9	210
118	Subcellular Localization, Stability, and <i>trans</i> -Cleavage Competence of the Hepatitis C Virus NS3-NS4A Complex Expressed in Tetracycline-Regulated Cell Lines. Journal of Virology, 2000, 74, 2293-2304.	3.4	248
119	Targeted gene transfer to hepatocellular carcinoma cellsin vitro using a novel monoclonal antibody?based gene delivery system. Hepatology, 1999, 29, 82-89.	7.3	46
120	Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology, 1999, 29, 1262-1271.	7.3	140
121	Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression. Journal of Medical Virology, 1999, 57, 217-222.	5.0	27
122	Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression. Journal of Medical Virology, 1999, 57, 217-222.	5.0	1
123	Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology, 1998, 28, 192-201.	7.3	149
124	Enhanced Gene Delivery and Expression in Human Hepatocellular Carcinoma Cells by Cationic Immunoliposomes. Journal of Liposome Research, 1997, 7, 127-141.	3.3	14
125	In vivo gene electroinjection and expression in rat liver. FEBS Letters, 1996, 389, 225-228.	2.8	380
126	Characterization of Cell Lines Allowing Tightly Regulated Expression of Hepatitis C Virus Core Protein. Virology, 1996, 222, 51-63.	2.4	210

#	Article	IF	CITATIONS
127	Characterization of three novel monoclonal antibodies against hepatitis C virus core protein. Journal of Medical Virology, 1996, 48, 234-241.	5.0	56
128	Specific targeting of human hepatocellular carcinoma cells by immunoliposomesin vitro. Hepatology, 1995, 22, 1527-1537.	7.3	22